Patients with NAFLD do not have severe portal hypertension in the absence of cirrhosis

Lucile Moga¹, Alexia Laroyenne², Hélène Larrue², Christophe Bureau³, Pierre-Emmanuel Rautou⁴

Affiliations

¹ Service d'Hépatologie, DMU Digest, Hôpital Beaujon, AP-HP, Clichy, France.
² Service d'Hépatologie, Hôpital Rangueil, CHU Toulouse, Toulouse, France.
³ Service d'Hépatologie, Hôpital Rangueil, CHU Toulouse, Toulouse, France; Université Paul Sabatier Toulouse 3, Toulouse, France. Electronic address: bureau.c@chu-toulouse.fr.
⁴ Service d'Hépatologie, DMU Digest, Hôpital Beaujon, AP-HP, Clichy, France; Université de Paris, Centre de Recherche sur l'Inflammation, Inserm, U1149, CNRS, ERL8252, Paris, France; Centre de Référence des Maladies Vasculaires du Foie, French Network for Rare Liver Diseases (FILFOIE), European Reference Network on Hepatological Diseases (ERN RARE-LIVER), Hôpital Beaujon, AP-HP, Clichy, France.

PMID: 33340573
DOI: 10.1016/j.jhep.2020.10.011

Comment

Patients with NAFLD do not have severe portal hypertension in the absence of cirrhosis

Lucile Moga et al. J Hepatol. 2021 May.

. 2021 May;74(5):1269-1270.

doi: 10.1016/j.jhep.2020.10.011. Epub 2020 Dec 16.

Authors

Lucile Moga¹, Alexia Laroyenne², Hélène Larrue², Christophe Bureau³, Pierre-Emmanuel Rautou⁴

Affiliations

¹ Service d'Hépatologie, DMU Digest, Hôpital Beaujon, AP-HP, Clichy, France.
² Service d'Hépatologie, Hôpital Rangueil, CHU Toulouse, Toulouse, France.
³ Service d'Hépatologie, Hôpital Rangueil, CHU Toulouse, Toulouse, France; Université Paul Sabatier Toulouse 3, Toulouse, France. Electronic address: bureau.c@chu-toulouse.fr.
⁴ Service d'Hépatologie, DMU Digest, Hôpital Beaujon, AP-HP, Clichy, France; Université de Paris, Centre de Recherche sur l'Inflammation, Inserm, U1149, CNRS, ERL8252, Paris, France; Centre de Référence des Maladies Vasculaires du Foie, French Network for Rare Liver Diseases (FILFOIE), European Reference Network on Hepatological Diseases (ERN RARE-LIVER), Hôpital Beaujon, AP-HP, Clichy, France.

PMID: 33340573
DOI: 10.1016/j.jhep.2020.10.011

No abstract available

Keywords: Portal hypertension; cirrhosis; hepatic venous pressure gradient; liver fibrosis; non-alcoholic fatty liver disease; steatosis.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest C.B., L.M., A.L., H.L., and P-E.R. have nothing to declare. Please refer to the accompanying ICMJE disclosure forms for further details.

Comment on

Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension.
Garcia-Tsao G, Bosch J, Kayali Z, Harrison SA, Abdelmalek MF, Lawitz E, Satapathy SK, Ghabril M, Shiffman ML, Younes ZH, Thuluvath PJ, Berzigotti A, Albillos A, Robinson JM, Hagerty DT, Chan JL, Sanyal AJ; IDN-6556-14 Investigators(‡). Garcia-Tsao G, et al. J Hepatol. 2020 May;72(5):885-895. doi: 10.1016/j.jhep.2019.12.010. Epub 2019 Dec 21. J Hepatol. 2020. PMID: 31870950 Clinical Trial.

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Patients with NAFLD do not have severe portal hypertension in the absence of cirrhosis

Affiliations

Patients with NAFLD do not have severe portal hypertension in the absence of cirrhosis

Authors

Affiliations

Conflict of interest statement

Comment on

Publication types

MeSH terms

LinkOut - more resources

Full Text Sources

Medical